Effect of Covid 19 Infection on Fetomaternal Outcome

COVID-19 Clinical Trial

Official title: Effect of Time of COVID 19 Infection on Fetomaternal Outcome, and Immunological Changes During the Disease Course

Status Active, not recruiting

Clinical Trial Summary

The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered for the first time in December 2019 in Wuhan (China) and the disease it causes is called coronavirus disease 2019 (COVID-19). Now, this pandemic is rapidly spreading all over the world.

Pregnant have higher rates of COVID-19, associated with hospitalizations, and severe in-hospital outcomes. Immune responses may have a potential role in the diagnosis, treatment, and prognosis of patients with COVID-19. So we need of identifying biomarkers for disease severity and progression.

Clinical Trial Description

It is important to define whether a novel virus is transmissible from a mother to her infant, vertical infection, and there are three possible mechanisms for vertical infection - intrauterine infection (including transplacental and ascending infections), intrapartum transmission (during delivery), and postpartum infection. These mechanisms have important implications that can influence obstetrical management decisions, best practice delivery options, and neonatal care (3).

Aim of work To detect the effect of time of infection by COVID 19 on the fetomaternal outcome including vertical transmission, and the immunological and genetic changes during the disease course.

Patients and Methods:

• All pregnant women eligible for the study will undergo detailed medical history.

• Each patient will have the following data: • Patient name. • Age. • Past medical and surgical history. • Menstrual history and contraceptive history: especially emphasis on Last Menstrual Period to determine the exact gestational age.

• Clinical examination of the patients: - General examination of vital data (blood pressure, pulse, temperature, respiratory rate). CBC, PT, PTT, RBS, ALT, AST, serum creatinine), and ultrasound will be done.

• Abdominal examination: to detect any abnormality as intrauterine growth restriction, with serial ultrasound estimation. ;

Related Conditions & MeSH terms

• COVID-19
• COVID-19 Pneumonia
• Fetal Growth Retardation
• Infections
• Pneumonia

• NCT number: NCT05160649
• Study type: Observational
• Source: Fayoum University
• Status: Active, not recruiting
• Start date: October 10, 2021
• Completion date: October 2023